A 'universal' cancer vaccine moves closer

via Cardiff University

Article Highlights

Researchers at Cardiff University have discovered a new type of killer T-cell that offers hope of a “one-size-fits-all” cancer therapy
T-cell therapies for cancer - where immune cells are removed, modified and returned to the patient’s blood to seek and destroy cancer cells - are the latest paradigm in cancer treatments
The most widely-used therapy, known as CAR-T, is personalised to each patient but targets only a few types of cancers and has not been successful for solid tumours, which make up the vast majority of cancers
Cardiff researchers have now discovered T-cells equipped with a new type of T-cell receptor (TCR) which recognises and kills most human cancer types, while ignoring healthy cells
This TCR recognises a molecule present on the surface of a wide range of cancer cells as well as in many of the body’s normal cells but, remarkably, is able to distinguish between healthy cells and cancerous ones, killing only the latter
The researchers said this meant it offered “exciting opportunities for pan-cancer, pan-population” immunotherapies not previously thought possible
T-cells equipped with the new TCR were shown, in the lab, to kill lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells, while ignoring healthy cells
To test the therapeutic potential of these cells in vivo, the researchers injected T-cells able to recognise MR1 into mice bearing human cancer and with a human immune system
This showed “encouraging” cancer-clearing results which the researchers said was comparable to the now NHS-approved CAR-T therapy in a similar animal model
The Cardiff group were further able to show that T-cells of melanoma patients modified to express this new TCR could destroy not only the patient’s own cancer cells, but also other patients’ cancer cells in the laboratory, regardless of the patient’s HLA type
Professor Andrew Sewell, lead author on the study and an expert in T-cells from Cardiff University’s School of Medicine, said it was “highly unusual” to find a TCR with such broad cancer specificity and this raised the prospect of “universal” cancer therapy
“We hope this new TCR may provide us with a different route to target and destroy a wide range of cancers in all individuals,” he said
“Current TCR-based therapies can only be used in a minority of patients with a minority of cancers
“Cancer-targeting via MR1-restricted T-cells is an exciting new frontier - it raises the prospect of a ‘one-size-fits-all’ cancer treatment; a single type of T-cell that could be capable of destroying many different types of cancers across the population
“There are plenty of hurdles to overcome however if this testing is successful, then I would hope this new treatment could be in use in patients in a few years’ time,” he said
“This is truly exciting and potentially a great step forward for the accessibility of cancer immunotherapy.”

The Complete Story: Discovery of new T-cell raises prospect of ‘universal’ cancer therapy

Cardiff University

Go deeper with Bing News on:

Universal cancer vaccine

Trudeau campaign rally cancelled over safety concerns from angry anti-vaccine protesters
Protesters who oppose masks, vaccines and lockdown measures to fight COVID-19 have dogged the Liberal leader on the campaign trail The Liberal campaign cancelled an early evening rally on Friday after ...
Trudeau campaign rally cancelled due to safety concerns with anti-vaccine protestors
It was the third such incident Friday where Trudeau was confronted by angry demonstrators upset with his government's push on vaccine passports and vaccine mandates for travellers.
FG tasks governors on protecting COVID-19 vaccines, cold storage
Executive Director, National Primary Health Care Development Agency (NPHCDA), Dr. Faisal Shuaib, has called on governors to provide oversight and resources to ensure COVID-19 ...
Despite approval to Zydus Cadila vaccine, kids' inoculation may not start anytime soon
Vaccination for adolescents and kids with serious comorbidities, however, are likely to start in October when sufficient doses of ZyCoV D is available.
Doubts grow over the future of AstraZeneca’s Covid vaccine
Government deal to buy 35m doses of Pfizer booster shots to be delivered next year adds to clouds over the Oxford-AZ jab ...

Go deeper with Google Headlines on:

Universal cancer vaccine

Novel Cancer Vaccine Combined With Pembrolizumab Shows Promise in Metastatic Melanoma - Targeted Oncology
August 12, 2021
Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic - GlobeNewswire
August 12, 2021
Universal Cancer Vaccine Candidate Presents Positive Long-term Benefits - Precision Vaccinations
May 11, 2021
The Search for a Cancer Vaccine: Have We Been Doing It All Wrong? - SynBioBeta
May 25, 2021
On the hunt for a ‘universal’ COVID-19 vaccine as Delta variant surges - Fortune
August 18, 2021

Go deeper with Bing News on:

Cancer vaccine

Past Infection May Better Protect Against Delta Than Vaccine, but
A prior infection from COVID-19 was more protective than vaccine-induced immunity in reducing the risk of infection and symptomatic illness from the Delta variant, according to a retrospective ...
Scancell receives MHRA approval for Phase I/II trial of cancer vaccine
The trial will assess the vaccine’s safety, immunological activity and preliminary efficacy, with early data expected next year. Scancell has received approval from the UK’s Medicines and Healthcare ...
Terumo and PhotonPharma partner to develop cancer vaccine
Terumo and PhotonPharma have teamed up and established an MOU to develop Innocell, a therapeutic vaccine for solid tumors.
I Had Cancer: Do I Need a Third COVID Vaccine Shot Now?
A doctor can help determine if an extra dose of the vaccine will mount a stronger defense against COVID-19 for people who are immunocompromised.
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
Boehringer Ingelheim terminated a partnership with CureVac on an mRNA lung cancer vaccine program. The cancellation of this deal shouldn't impact other mRNA cancer vaccine programs for Moderna, ...